Newron Rises After Parkinson’s Drug Study SucceedsSimeon Bennett
Newron Pharmaceuticals SpA, an Italian developer of an experimental treatment for Parkinson’s disease, rose to the highest in almost six weeks after saying the drug succeeded in two clinical trials.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- This $14 Million Atlanta Home With Bunker Is ‘Safest in America’
- GE's New CEO Vows Sweeping Change After ‘Unacceptable’ Report
- These Cities Make NYC Housing Look Dirt Cheap
- Separatists Pledge to Fight On After Spain Moves to Oust Catalan Leaders
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself